[
    [
        {
            "time": "2018-03-01",
            "original_text": "Top Stock Reports for Coca-Cola, Eli Lilly & Occidental Petroleum",
            "features": {
                "keywords": [
                    "Coca-Cola",
                    "Eli Lilly",
                    "Occidental Petroleum"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "consumer goods",
                    "pharmaceuticals",
                    "energy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top Stock Reports for Coca-Cola, Eli Lilly & Occidental Petroleum",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "What’s AstraZeneca’s Valuation in March 2018?",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "valuation"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What’s AstraZeneca’s Valuation in March 2018?",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-03-20",
            "original_text": "Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails",
            "features": {
                "keywords": [
                    "MRK",
                    "cancer deal",
                    "DERM",
                    "acne candidate fails"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology",
            "features": {
                "keywords": [
                    "Maura Dickler",
                    "Lilly Oncology",
                    "Vice President",
                    "Late Phase Development"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-30",
            "original_text": "Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails",
            "features": {
                "keywords": [
                    "MRK",
                    "cancer deal",
                    "DERM",
                    "acne candidate fails"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: MRK Signs New Cancer Deal, DERM's Acne Candidate Fails",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]